218 related articles for article (PubMed ID: 9248869)
1. An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group.
Berk M; du Plessis AD; Birkett M; Richardt D
Int Clin Psychopharmacol; 1997 May; 12(3):137-40. PubMed ID: 9248869
[TBL] [Abstract][Full Text] [Related]
2. Duloxetine: a new serotonin/noradrenaline reuptake inhibitor for the treatment of depression.
Rabasseda X
Drugs Today (Barc); 2004 Sep; 40(9):773-90. PubMed ID: 15538550
[TBL] [Abstract][Full Text] [Related]
3. Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder.
Bech P; Kajdasz DK; Porsdal V
Psychopharmacology (Berl); 2006 Oct; 188(3):273-80. PubMed ID: 16960699
[TBL] [Abstract][Full Text] [Related]
4. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
Goldstein DJ; Mallinckrodt C; Lu Y; Demitrack MA
J Clin Psychiatry; 2002 Mar; 63(3):225-31. PubMed ID: 11926722
[TBL] [Abstract][Full Text] [Related]
5. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
[TBL] [Abstract][Full Text] [Related]
6. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode.
Martinez JM; Katon W; Greist JH; Kroenke K; Thase ME; Meyers AL; Edwards SE; Marangell LB; Shoemaker S; Swindle R
Int Clin Psychopharmacol; 2012 Jan; 27(1):17-26. PubMed ID: 22027844
[TBL] [Abstract][Full Text] [Related]
7. Duloxetine pharmacology: profile of a dual monoamine modulator.
Karpa KD; Cavanaugh JE; Lakoski JM
CNS Drug Rev; 2002; 8(4):361-76. PubMed ID: 12481192
[TBL] [Abstract][Full Text] [Related]
8. Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study.
Seguí J; López-Muñoz F; Alamo C; Camarasa X; García-García P; Pardo A
J Psychopharmacol; 2010 Aug; 24(8):1201-7. PubMed ID: 19282423
[TBL] [Abstract][Full Text] [Related]
9. Effects of duloxetine on painful physical symptoms associated with depression.
Goldstein DJ; Lu Y; Detke MJ; Hudson J; Iyengar S; Demitrack MA
Psychosomatics; 2004; 45(1):17-28. PubMed ID: 14709757
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week study with plasma levels.
Volonteri LS; Colasanti A; Cerveri G; Fiorentini A; De Gaspari IF; Mauri MC; Valli A; Papa P; Mencacci C
J Psychopharmacol; 2010 Aug; 24(8):1193-9. PubMed ID: 19406851
[TBL] [Abstract][Full Text] [Related]
11. Is there a place for duloxetine?
Drug Ther Bull; 2007 Apr; 45(4):29-32. PubMed ID: 17451072
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
[TBL] [Abstract][Full Text] [Related]
13. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
Lam RW; Lönn SL; Despiégel N
Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
[TBL] [Abstract][Full Text] [Related]
14. Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors.
Sheehan DV; Mancini M; Wang J; Berggren L; Cao H; Dueñas HJ; Yue L
Hum Psychopharmacol; 2016 Jan; 31(1):53-63. PubMed ID: 26331440
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder.
Thase ME; Pritchett YL; Ossanna MJ; Swindle RW; Xu J; Detke MJ
J Clin Psychopharmacol; 2007 Dec; 27(6):672-6. PubMed ID: 18004135
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study.
Bellino S; Paradiso E; Bozzatello P; Bogetto F
J Psychopharmacol; 2010 Mar; 24(3):333-9. PubMed ID: 18719047
[TBL] [Abstract][Full Text] [Related]
17. Rescue pharmacotherapy with duloxetine for selective serotonin reuptake inhibitor nonresponders in late-life depression: outcome and tolerability.
Karp JF; Whyte EM; Lenze EJ; Dew MA; Begley A; Miller MD; Reynolds CF
J Clin Psychiatry; 2008 Mar; 69(3):457-63. PubMed ID: 18251622
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials.
Kornstein SG; Wohlreich MM; Mallinckrodt CH; Watkin JG; Stewart DE
J Clin Psychiatry; 2006 May; 67(5):761-70. PubMed ID: 16841626
[TBL] [Abstract][Full Text] [Related]
19. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
[TBL] [Abstract][Full Text] [Related]
20. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.
Detke MJ; Lu Y; Goldstein DJ; Hayes JR; Demitrack MA
J Clin Psychiatry; 2002 Apr; 63(4):308-15. PubMed ID: 12000204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
